Paladin wins commercialization rights to Apeiron APN311 in Canada, Sub-Saharan Africa
APN311 is a monoclonal chimeric antibody developed to treat neuroblastoma, a malignant tumor developing from nerve tissue and most common in children below five years. Paladin Labs interim
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.